Latest Pharma and Biotech News
Biotechnology
26 November 2024 US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement.
Today's issue
Refine Search
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
Biotechnology
Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was trading 83% lower at midday on Thursday. 25 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab mafodotin in combinations with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]) for multiple myeloma patients who have received at least one prior line of therapy. 25 November 2024
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $135 million Series B financing round. 25 November 2024
Biotechnology
StemCyte, a subsidiary of StemCyte International, has secured approval from the US Food and Drug Administration for Regenecyte, a cord blood-derived stem cell therapy. 25 November 2024
All news
Biotechnology
Swiss pharma giant Novartis has reported the first interpretable year one results of the Phase III MERLIN study. 1 June 2021
Biotechnology
Shares in French drugmaker Sanofi looked set to close 1% lower on Tuesday after announcing an update on the venglustat clinical program. 1 June 2021
Biotechnology
US biotech Corbus Pharmaceuticals today announced the expansion of its portfolio into immuno-oncology through licensing deals for two new monoclonal antibodies (MAbs), CRB-601 (a high potency anti-avb8 MAb) and CRB-602 (anti-avb6/avb8 MAb), that target integrins to inhibit activation of transforming growth factor β (TGFβ), from the University of California San Francisco and Panorama Research. 1 June 2021
Biotechnology
A five-month old baby has become the first patient to receive Novartis’ Zolgensma (onasemnogene abeparvovec) on the National Health Service (NHS). 1 June 2021
Biotechnology
Heartseed and Danish pharma major Novo Nordisk have entered into an exclusive worldwide collaboration and licence agreement for development, manufacturing and commercialization of the Japanese start-up’s lead asset, HS-001. 1 June 2021
Biotechnology
South Korean contract development and manufacturing organization (CDMO) Samsung Biologics plans to add mRNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier part of the year in 2022. 1 June 2021
Biotechnology
Swiss biotech Santhera Pharmaceuticals has announced positive key results form a Phase IIb study of vamorolone in the treatment of Duchenne muscular dystrophy (DMD). 1 June 2021
Biotechnology
Californian cytokine storm syndrome specialist Humanigen on Friday announced it has submitted an application to the US Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for lenzilumab for the treatment of patients hospitalized with COVID-19. 1 June 2021
Biotechnology
Russian biotech firm R-Pharm Group and Beijing Health Guard Biotechnology have entered into a license agreement on the development and commercialization of a nonavalent human papillomavirus vaccines (HPV) vaccine in Russia. 1 June 2021
Biotechnology
The US Food and Drug Administration approved Lumakras (sotorasib: AMG 510) as the first treatment for adult patients with non-small cell lung cancer (NSCLC) whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. 29 May 2021
Biotechnology
The US Food and Drug Administration has granted accelerated approval to Truseltiq (infigratinib), a kinase inhibitor for adults with previously treated, unresectable locally-advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. 29 May 2021
Biotechnology
Eli Lilly has received a subpoena from the US Department of Justice (DoJ) requesting the production of certain documents relating to its manufacturing site in Branchburg, New Jersey. 28 May 2021
Biotechnology
A positive reimbursement decision in the UK will enable Tremfya (guselkumab) to be offered for active psoriatic arthritis (PsA) through the country’s National Health Service (NHS). 28 May 2021
Biotechnology
German family-owned pharma major Boehringer Ingelheim recently announced that its product, BI 425809, has received Breakthrough Therapy designation (BTD) by the US Food and Drug Administration for cognitive impairment associated with schizophrenia (CIAS). 28 May 2021
Biotechnology
The worldwide nanomedicine market, which was worth $141.34 billion in 2020, will rise to $258.11 billion by 2025. 27 May 2021
Biotechnology
ValiRx, a UK oncology-focussed biotech, today announced that further to the notification made on November 10, 2020 it has concluded its agreement in relation to the evaluation of the KTH222 peptide as a drug candidate for treating patients with ovarian cancer. 27 May 2021
Biotechnology
The US Food and Drug Administration has granted an Emergency Use Authorization (EUA) for sotrovimab (previously VIR-7831), an investigational single-dose monoclonal antibody, for the treatment of mild-to-moderate COVID-19. 27 May 2021
Biotechnology
The US regulator will consider a submission for novel cancer therapy ciltacabtagene autoleucel (cilta-cel) under the agency’s Priority Review scheme, with a decision expected by November 29. 27 May 2021
Biotechnology
Spanish biopharma PharmaMar has announced the final results of its APLICOV-PC trial with Aplidin (plitidepsin) for the treatment of adults with COVID-19 requiring hospitalization, which met the primary safety endpoint and showed clinical efficacy. 26 May 2021
Biotechnology
Cell therapy specialist and Bayer subsidiary BlueRock Therapeutics is to work together with fellow USA-based company Senti Biosciences (Senti Bio). 26 May 2021
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze